{"title":"大型单中心elexaftor /Tezacaftor/Ivacaftor治疗囊性纤维化患者的临床经验,基线FEV1预测低于40%","authors":"R. Kapolka, W. Hunt","doi":"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":411070,"journal":{"name":"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS","volume":"28 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Large Single Center’s Clinical Experience with Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis and a Baseline FEV1 of Less Than 40 Percent Predicted\",\"authors\":\"R. Kapolka, W. Hunt\",\"doi\":\"10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":411070,\"journal\":{\"name\":\"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS\",\"volume\":\"28 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"TP32. TP032 EPIDEMIOLOGY, BIOMARKERS, AND THERAPY IN CF AND NON-CF BRONCHIECTASIS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a2025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Large Single Center’s Clinical Experience with Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis and a Baseline FEV1 of Less Than 40 Percent Predicted